
## Elena Goicoechea De Jorge

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4778868/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Factor H–Related Protein 1 Drives Disease Susceptibility and Prognosis in C3 Glomerulopathy. Journal of the American Society of Nephrology: JASN, 2022, 33, 1137-1153.	6.1	12
2	A Family Affair: Addressing the Challenges of Factor H and the Related Proteins. Frontiers in Immunology, 2021, 12, 660194.	4.8	26
3	Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases. Blood, 2021, 137, 3484-3494.	1.4	17
4	Defining the Glycosaminoglycan Interactions of Complement Factor H–Related Protein 5. Journal of Immunology, 2021, 207, 534-541.	0.8	9
5	Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1287-1298.	4.5	36
6	Familial risk of developing atypical hemolytic-uremic syndrome. Blood, 2020, 136, 1558-1561.	1.4	18
7	Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2018, 29, 240-249.	6.1	34
8	How novel structures inform understanding of complement function. Seminars in Immunopathology, 2018, 40, 3-14.	6.1	6
9	Low FHR-5 levels contribute to infection-triggered haemolytic uraemic syndrome/membranoproliferative glomerulonephritis. Molecular Immunology, 2018, 102, 155.	2.2	0
10	Common and rare genetic variants of complement components in human disease. Molecular Immunology, 2018, 102, 42-57.	2.2	18
11	Elevated factor H–related protein 1 and factor H pathogenic variants decrease complement regulation inÂlgA nephropathy. Kidney International, 2017, 92, 953-963.	5.2	87
12	Factor H-related proteins determine complement-activating surfaces. Trends in Immunology, 2015, 36, 374-384.	6.8	130
13	Factor H–Related Protein 5 Interacts with Pentraxin 3 and the Extracellular Matrix and Modulates Complement Activation. Journal of Immunology, 2015, 194, 4963-4973.	0.8	75
14	C3 glomerulopathy: consensus report. Kidney International, 2013, 84, 1079-1089.	5.2	505
15	Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4685-4690.	7.1	243
16	Design and Evaluation of Meningococcal Vaccines through Structure-Based Modification of Host and Pathogen Molecules. PLoS Pathogens, 2012, 8, e1002981.	4.7	53
17	A Hybrid CFHR3-1 Gene Causes Familial C3 Glomerulopathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 1155-1160.	6.1	120
18	Acute Presentation and Persistent Glomerulonephritis Following Streptococcal Infection in a Patient With Heterozygous Complement Factor H–Related Protein 5 Deficiency. American Journal of Kidney Diseases, 2012, 60, 121-125.	1.9	95

#	Article	IF	CITATIONS
19	Recurrence of Complement Factor H-Related Protein 5 Nephropathy in a Renal Transplant. American Journal of Transplantation, 2011, 11, 152-155.	4.7	37
20	Differential binding of CFHR5 and factor H to C3 metabolites suggests that these two proteins regulate complement activation at different stages. Molecular Immunology, 2011, 48, 1675.	2.2	0
21	The Development of Atypical Hemolytic Uremic Syndrome Depends on Complement C5. Journal of the American Society of Nephrology: JASN, 2011, 22, 137-145.	6.1	105
22	Human CFH rapidly reverses renal complement deposition in factor H-deficient mice. Molecular Immunology, 2010, 47, 2201-2201.	2.2	0
23	Atypical hemolytic uremic syndrome: telling the difference between H and Y. Kidney International, 2010, 78, 721-723.	5.2	7
24	Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney International, 2010, 78, 279-286.	5.2	94
25	Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet, The, 2010, 376, 794-801.	13.7	298
26	Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population. Clinical and Experimental Immunology, 2009, 155, 59-64.	2.6	13
27	A mutant complement factor H-related 5 protein is associated with familial C3 glomerulonephritis. Molecular Immunology, 2009, 46, 2822.	2.2	2
28	Insights into the role of complement dysregulation in atypical haemolytic uremic syndrome. Molecular Immunology, 2009, 46, 2851.	2.2	1
29	Mutations in Proteins of the Alternative Pathway of Complement and the Pathogenesis of Atypical Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2008, 52, 171-180.	1.9	24
30	Genetic deficiency of complement factor H in a patient with age-related macular degeneration and membranoproliferative glomerulonephritis. Molecular Immunology, 2008, 45, 2897-2904.	2.2	46
31	Complement Factor H Binds to Denatured Rather than to Native Pentameric C-reactive Protein. Journal of Biological Chemistry, 2008, 283, 30451-30460.	3.4	82
32	Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. Journal of Experimental Medicine, 2007, 204, 1249-1256.	8.5	267
33	Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 240-245.	7.1	429
34	Spontaneous haemolytic uraemic syndrome (HUS) in factor H-deficient mice transgenic for murine factor H protein lacking the five C-terminal domains (FHΔ16–20). Molecular Immunology, 2007, 44, 227-228.	2.2	0
35	The Spanish atypical haemolytic uraemic syndrome registry: A genetic update. Molecular Immunology, 2007, 44, 3923.	2.2	2
36	Factor H allele-specific quantification in Tyr402His heterozygotes reveals the existence of low-expression alleles associated with atypical haemolytic uraemic syndrome. Molecular Immunology, 2007, 44, 3925.	2.2	2

#	Article	IF	CITATIONS
37	Novel complement factor H mutation in SCR7 in a patient with age-related macular degeneration and membranoproliferative glomerulonephritis type II. Molecular Immunology, 2007, 44, 3973.	2.2	0
38	Analytical ultracentrifugation analysis of the human complement factor H variants 402His and 402Tyr. Molecular Immunology, 2007, 44, 3982.	2.2	1
39	The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Human Mutation, 2007, 28, 222-234.	2.5	160
40	Translational Mini-Review Series on Complement Factor H: Genetics and disease associations of human complement factor H. Clinical and Experimental Immunology, 2007, 151, 1-13.	2.6	252
41	Insights into hemolytic uremic syndrome: Segregation of three independent predisposition factors in a large, multiple affected pedigree. Molecular Immunology, 2006, 43, 1769-1775.	2.2	122
42	Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Human Molecular Genetics, 2005, 14, 703-712.	2.9	272
43	Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Human Molecular Genetics, 2005, 14, 1107-1107.	2.9	7
44	The human complement factor H: functional roles, genetic variations and disease associations. Molecular Immunology, 2004, 41, 355-367.	2.2	514
45	Molecular analyses of the HGO gene mutations in Turkish alkaptonuria patients suggest that the R58fs mutation originated from Central Asia and was spread throughout Europe and Anatolia by human migrations. Journal of Inherited Metabolic Disease, 2003, 26, 17-23.	3.6	19
46	Alkaptonuria in the Dominican Republic: identification of the founder AKU mutation and further evidence of mutation hot spots in the HGO gene. Journal of Medical Genetics, 2002, 39, 40e-40.	3.2	32
47	Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy. CKJ: Clinical Kidney Journal, 0, , .	2.9	3